4.7 Article

Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 219, Issue 8, Pages -

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20220131

Keywords

-

Funding

  1. Howard Hughes Medical Institute
  2. Rockefeller University
  3. St. Giles Foundation
  4. National Institutes of Health (NIH) [R01AI088364, R01AI63029]
  5. National Center for Advancing Translational Sciences
  6. NIH Clinical and Translational Science Award program [UL1 TR001866]
  7. Emergent Ventures
  8. Mercatus Center at George Mason University
  9. Yale Center for Mendelian Genomics
  10. National Human Genome Research Institute [UM1HG006504, U24HG008956]
  11. Yale High Performance Computing Center [S10OD018521]
  12. Fisher Center for Alzheimer's Research Foundation
  13. JPB Foundation
  14. Meyer Foundation
  15. French National Research Agency (ANR) [ANR-10-IAHU-01]
  16. Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence [ANR-10-LABX-62-IBEID]
  17. French Foundation for Medical Research [EQU201903007798]
  18. ANR GenMISC [ANR-21-COVR-039]
  19. ANRS-COV05
  20. ANR GENVIR [ANR-20-CE93-003]
  21. ANR AABIFNCOV [ANR-20-CO11-0001]
  22. European Union [824110]
  23. Square Foundation
  24. Grandir-Fonds de solidarite pour l'enfance
  25. Fondation du Souffle
  26. SCOR Corporate Foundation for Science
  27. French Ministry of Higher Education, Research, and Innovation
  28. Institut National de la Sante et de la Recherche Medicale (INSERM)
  29. REACTing-INSERM
  30. University of Paris
  31. NIH [P01AI138398-S1, 2U19AI111825, R01AI091707-10S1, R01AI161444]
  32. George Mason University
  33. G. Harold and Leila Y. Mathers Charitable Foundation
  34. Bawd Foundation
  35. Francois Wallace Monahan Postdoctoral Fellowship at The Rockefeller University
  36. European Molecular Biology Organization Long-Term Fellowship [ALTF 380-2018]
  37. MD-PhD program of the Imagine Institute
  38. Fondation Bettencourt Schueller
  39. Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH
  40. Regione Lazio [A0375-2020-36663]
  41. CSL Behring Chair of Primary Immunodeficiencies
  42. CSL-Behring Research Grant
  43. KU Leuven C1 [C16/18/007]
  44. VIB GC PID grant
  45. FWO [G0C8517N, G0B5120N, G0E8420N, 11F4421N]
  46. Jeffrey Modell Foundation
  47. European Research Council [948959]
  48. ERN-RITA
  49. Singapore National Medical Research Council [COVID19RF-001, COVID19RF-0008, COVID19RF-060]
  50. A*STAR COVID-19 research funding [H/20/04/g1/006]
  51. Instituto de Salud Carlos III [COV20_01333, COV20_01334]
  52. Spanish Ministry of Science and Innovation [RTC-2017-6471-1]
  53. Cabildo Insular de Tenerife [CGIEU0000219140]
  54. personal FWO [11F4421N]
  55. European Research Council (ERC) [948959] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

In an international cohort of 112 hospitalized children with COVID-19 pneumonia, 12 children with recessive inborn errors of type I interferon immunity were identified. These deficiencies may contribute to the development of COVID-19 pneumonia in children. Additionally, these deficiencies were not found in individuals without pneumonia from SARS-CoV-2 infection.
In an international cohort of 112 children hospitalized for moderate to critical COVID-19 pneumonia, we identified 12 children with one of four known recessive inborn errors of type I interferon immunity: X-linked TLR7 and autosomal IFNAR1, STAT2, and TYK2 deficiencies. Recessive or dominant inborn errors of type I interferon (IFN) immunity can underlie critical COVID-19 pneumonia in unvaccinated adults. The risk of COVID-19 pneumonia in unvaccinated children, which is much lower than in unvaccinated adults, remains unexplained. In an international cohort of 112 children (<16 yr old) hospitalized for COVID-19 pneumonia, we report 12 children (10.7%) aged 1.5-13 yr with critical (7 children), severe (3), and moderate (2) pneumonia and 4 of the 15 known clinically recessive and biochemically complete inborn errors of type I IFN immunity: X-linked recessive TLR7 deficiency (7 children) and autosomal recessive IFNAR1 (1), STAT2 (1), or TYK2 (3) deficiencies. Fibroblasts deficient for IFNAR1, STAT2, or TYK2 are highly vulnerable to SARS-CoV-2. These 15 deficiencies were not found in 1,224 children and adults with benign SARS-CoV-2 infection without pneumonia (P = 1.2 x 10(-11)) and with overlapping age, sex, consanguinity, and ethnicity characteristics. Recessive complete deficiencies of type I IFN immunity may underlie similar to 10% of hospitalizations for COVID-19 pneumonia in children.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available